Similarly, a Spanish group analyzed the efficacy and safety of SGLT2 inhibitors in KT recipients with T2DM and PTDM and found a significant increase in serum Mg levels after treatment initiation [149]. Here, SLC5A2 is linked to type 2 diabetes mellitus.